losartan has been researched along with Bright Disease in 32 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Bright Disease: A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To conduct a systematic review of the efficacy and safety of Shenyankangfu tablets in combination with losartan potassium in the treatment of chronic glomerulonephritis." | 9.22 | Meta-analysis of the effectiveness and safety of Shenyankangfu tablets combined with losartan potassium in the treatment of chronic glomerulonephritis. ( Chen, XF; Feng, PF; Sheng, N; Zhu, LX, 2022) |
| " The aim of this study was to evaluate the effects of low-dose (25 mg) losartan on proteinuria and tubular injury extent." | 9.11 | Randomized, controlled study of the effects of losartan versus enalapril in small doses on proteinuria and tubular injury in primary glomerulonephritis. ( Lysiak-Szydłowska, W; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L, 2005) |
| " The aim of the present study was to investigate renal and metabolic effects of specific AT-1 receptor blocker-losartan in patients with primary glomerulonephritis." | 9.10 | Short-term effects of angiotensin II receptor blockade in patients with primary glomerulonephritis: pilot study. ( Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L, 2002) |
| "Carvedilol was not found to be as effective as ACEIs and AT1ras in decreasing proteinuria and preserving renal function." | 6.73 | Comparison of higher dose of losartan treatment with losartan plus carvedilol and losartan plus ramipril in patients with glomerulonephritis and proteinuria. ( Akdag, I; Arabul, M; Dilek, K; Ersoy, A; Gullulu, M; Kahvecioglu, S; Yavuz, M; Yurtkuran, M, 2007) |
| "To conduct a systematic review of the efficacy and safety of Shenyankangfu tablets in combination with losartan potassium in the treatment of chronic glomerulonephritis." | 5.22 | Meta-analysis of the effectiveness and safety of Shenyankangfu tablets combined with losartan potassium in the treatment of chronic glomerulonephritis. ( Chen, XF; Feng, PF; Sheng, N; Zhu, LX, 2022) |
| "The results of this trial will provide solid data for use in evidence-based medicine with respect to the efficacy and safety of Shenyankangfu tablets for control of proteinuria in patients with primary glomerulonephritis compared to those of losartan potassium." | 5.19 | Efficacy and safety of Shenyankangfu tablets for primary glomerulonephritis: study protocol for a randomized controlled trial. ( Cai, GY; Chen, XM; Deng, YY; Fang, JA; He, YN; Kou, J; Lin, HL; Nie, LF; Wu, J; Xie, YS; Yang, HT, 2014) |
| "Japanese patients with renal insufficiency were randomly assigned to receive either an ACE inhibitor (benazepril 1." | 5.12 | A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy. ( Kanno, Y; Shoda, J; Suzuki, H, 2006) |
| "The study shows that combination therapy with very small doses of losartan and benazepril was more effective in reducing proteinuria than greater doses of either agent in monotherapy, and this greater antiproteinuric efficacy was independent of changes in BP." | 5.11 | Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis. ( Korejwo, G; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L; Zdrojewski, Z, 2004) |
| "This was a prospective, randomized, 9-month study of the effects of low doses of losartan (25 mg; n = 18) versus enalapril (10 mg; n = 18) versus the combination of losartan (25 mg) and enalapril (10 mg) (n = 16) on proteinuria, kidney function and metabolic profile in 54 patients with biopsy-proven chronic glomerulonephritis, hypertension and normal or slightly impaired kidney function." | 5.11 | Low-dose angiotensin II receptor antagonists and angiotensin II-converting enzyme inhibitors alone or in combination for treatment of primary glomerulonephritis. ( Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L, 2004) |
| " The aim of this study was to evaluate the effects of low-dose (25 mg) losartan on proteinuria and tubular injury extent." | 5.11 | Randomized, controlled study of the effects of losartan versus enalapril in small doses on proteinuria and tubular injury in primary glomerulonephritis. ( Lysiak-Szydłowska, W; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L, 2005) |
| " The aim of the present study was to investigate renal and metabolic effects of specific AT-1 receptor blocker-losartan in patients with primary glomerulonephritis." | 5.10 | Short-term effects of angiotensin II receptor blockade in patients with primary glomerulonephritis: pilot study. ( Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L, 2002) |
| "Our data show that the effects of losartan and amlodipine on the absolute mean reduction of blood pressure and proteinuria in non-diabetic nephropathy patients are similar between the different ACE or AGT genotypes." | 3.73 | [Pharmacogenetics of angiotensin system in non diabetic nephropathy]. ( Alvarez, V; Arias, M; Campistol, JM; Coto, E; Fernández Andrade, C; Galcerán, JM; Luño, J; Marín, R; Poveda, R; Praga, M; Rivera, F; Vallés, M, 2005) |
| " The incidence of adverse reactions was not different among the 3 groups (P>0." | 2.79 | Efficacy and safety of Abelmoschus manihot for primary glomerular disease: a prospective, multicenter randomized controlled clinical trial. ( Chang, M; Chen, X; Ding, XQ; Fu, P; Guan, GJ; Hao, L; He, LQ; He, YN; Hu, Z; Li, P; Lin, HL; Lin, S; Liu, ZS; Mei, CL; Miao, LN; Wang, JQ; Wang, L; Wang, R; Wu, XF; Xie, RJ; Xing, CY; Yin, AP; Yuan, FH; Zhang, AP; Zhang, L; Zhang, M; Zhao, JY; Zhou, CH, 2014) |
| "Carvedilol was not found to be as effective as ACEIs and AT1ras in decreasing proteinuria and preserving renal function." | 2.73 | Comparison of higher dose of losartan treatment with losartan plus carvedilol and losartan plus ramipril in patients with glomerulonephritis and proteinuria. ( Akdag, I; Arabul, M; Dilek, K; Ersoy, A; Gullulu, M; Kahvecioglu, S; Yavuz, M; Yurtkuran, M, 2007) |
| "The etiology of CKD was type 2 diabetes mellitus in 12 and glomerulonephritis in 4 patients." | 2.71 | Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade. ( Agarwal, R, 2003) |
| "Treatment with enalapril or losartan also decreased renal plasminogen activator inhibitor-1 in TSLPtg mice, assessed by immunohistochemistry and quantitative real-time reverse transcriptase-PCR." | 1.35 | Renin-angiotensin system blockade is renoprotective in immune complex-mediated glomerulonephritis. ( Alexandrescu, S; Alpers, CE; Banas, M; Guo, S; Hudkins, KL; Iyoda, M; Kowalewska, J; Spencer, M; Wang, L; Wietecha, TA; Yi, K, 2008) |
| " Group 2 (n = 5) was treated with enalapril at a dosage of 50 mg/l in drinking water starting at 6 weeks of age." | 1.29 | Effects of an angiotensin II receptor antagonist on the progression of renal failure in hyperlipidemic Imai rats. ( Baba, N; Sakemi, T, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (21.88) | 18.2507 |
| 2000's | 18 (56.25) | 29.6817 |
| 2010's | 5 (15.63) | 24.3611 |
| 2020's | 2 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, PF | 1 |
| Chen, XF | 1 |
| Sheng, N | 1 |
| Zhu, LX | 1 |
| Binz-Lotter, J | 1 |
| Jüngst, C | 1 |
| Rinschen, MM | 1 |
| Koehler, S | 1 |
| Zentis, P | 1 |
| Schauss, A | 1 |
| Schermer, B | 1 |
| Benzing, T | 1 |
| Hackl, MJ | 1 |
| Arias, SC | 1 |
| Valente, CP | 1 |
| Machado, FG | 1 |
| Fanelli, C | 1 |
| Origassa, CS | 1 |
| de Brito, T | 1 |
| Camara, NO | 1 |
| Malheiros, DM | 2 |
| Zatz, R | 1 |
| Fujihara, CK | 1 |
| Zhang, L | 1 |
| Li, P | 1 |
| Xing, CY | 1 |
| Zhao, JY | 1 |
| He, YN | 2 |
| Wang, JQ | 1 |
| Wu, XF | 1 |
| Liu, ZS | 1 |
| Zhang, AP | 1 |
| Lin, HL | 2 |
| Ding, XQ | 2 |
| Yin, AP | 1 |
| Yuan, FH | 1 |
| Fu, P | 1 |
| Hao, L | 1 |
| Miao, LN | 1 |
| Xie, RJ | 1 |
| Wang, R | 1 |
| Zhou, CH | 1 |
| Guan, GJ | 1 |
| Hu, Z | 1 |
| Lin, S | 1 |
| Chang, M | 1 |
| Zhang, M | 1 |
| He, LQ | 2 |
| Mei, CL | 1 |
| Wang, L | 2 |
| Chen, X | 1 |
| Kou, J | 1 |
| Wu, J | 1 |
| Yang, HT | 1 |
| Fang, JA | 1 |
| Deng, YY | 1 |
| Xie, YS | 1 |
| Nie, LF | 2 |
| Cai, GY | 1 |
| Chen, XM | 1 |
| Wu, F | 1 |
| Zhang, PQ | 1 |
| Wang, XQ | 1 |
| Fu, XJ | 1 |
| Peng, W | 1 |
| Wang, Y | 1 |
| Li, J | 1 |
| Bi, YP | 1 |
| Mi, XH | 1 |
| Desbuards, N | 1 |
| Hyvelin, JM | 1 |
| Machet, MC | 1 |
| Eder, V | 1 |
| Garrigue, MA | 1 |
| Halimi, JM | 1 |
| Antier, D | 1 |
| Grosch, S | 1 |
| Van Overmeire, L | 1 |
| Krzesinski, JM | 1 |
| Bovy, C | 1 |
| Agarwal, R | 1 |
| Zhou, QL | 1 |
| Deng, SL | 1 |
| Yang, JH | 1 |
| Tang, X | 1 |
| Rutkowski, P | 4 |
| Tylicki, L | 4 |
| Renke, M | 4 |
| Korejwo, G | 1 |
| Zdrojewski, Z | 1 |
| Rutkowski, B | 4 |
| Ma, J | 1 |
| Matsusaka, T | 1 |
| Yang, H | 1 |
| Kawachi, H | 1 |
| Shimizu, F | 1 |
| Isaka, Y | 1 |
| Imai, E | 1 |
| Kon, V | 1 |
| Ichikawa, I | 1 |
| Graciano, ML | 1 |
| Cavaglieri, Rde C | 1 |
| Dellê, H | 1 |
| Dominguez, WV | 1 |
| Casarini, DE | 1 |
| Noronha, IL | 1 |
| Lysiak-Szydłowska, W | 1 |
| Aldigier, JC | 1 |
| Kanjanbuch, T | 1 |
| Ma, LJ | 1 |
| Brown, NJ | 1 |
| Fogo, AB | 1 |
| Coto, E | 1 |
| Marín, R | 1 |
| Alvarez, V | 1 |
| Praga, M | 1 |
| Fernández Andrade, C | 1 |
| Arias, M | 1 |
| Poveda, R | 1 |
| Vallés, M | 1 |
| Galcerán, JM | 1 |
| Luño, J | 1 |
| Rivera, F | 1 |
| Campistol, JM | 1 |
| Shoda, J | 1 |
| Kanno, Y | 1 |
| Suzuki, H | 1 |
| Kahvecioglu, S | 1 |
| Akdag, I | 1 |
| Gullulu, M | 2 |
| Arabul, M | 1 |
| Ersoy, A | 2 |
| Dilek, K | 2 |
| Yavuz, M | 2 |
| Yurtkuran, M | 2 |
| Guo, S | 1 |
| Kowalewska, J | 1 |
| Wietecha, TA | 1 |
| Iyoda, M | 1 |
| Yi, K | 1 |
| Spencer, M | 1 |
| Banas, M | 1 |
| Alexandrescu, S | 1 |
| Hudkins, KL | 1 |
| Alpers, CE | 1 |
| Piecha, G | 1 |
| Koleganova, N | 1 |
| Gross, ML | 1 |
| Geldyyev, A | 1 |
| Adamczak, M | 1 |
| Ritz, E | 1 |
| Sakemi, T | 1 |
| Baba, N | 1 |
| Higueruelo, S | 1 |
| Romero, R | 1 |
| Ots, M | 1 |
| Mackenzie, HS | 1 |
| Troy, JL | 1 |
| Rennke, HG | 1 |
| Brenner, BM | 1 |
| Kaysen, GA | 1 |
| Webster, S | 1 |
| Al-Bander, H | 1 |
| Jones, H | 1 |
| Hutchison, FN | 1 |
| Kutyrina, IM | 1 |
| Tareeva, IE | 1 |
| Nosikov, VV | 1 |
| Kamyshova, ES | 1 |
| Gorashko, NM | 1 |
| Chistiakov, DA | 1 |
| Okonova, EB | 1 |
| Troepol'skaia, OV | 1 |
| Peters, H | 2 |
| Border, WA | 2 |
| Noble, NA | 2 |
| Usta, M | 1 |
| Hutchinson, FN | 1 |
| Webster, SK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy: a Multicentre, Double-blind, Double-dummy, Randomized Controlled Trial[NCT02231125] | Phase 4 | 1,600 participants (Anticipated) | Interventional | 2014-09-30 | Recruiting | ||
| Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease：a Multicentre Open Study[NCT02231138] | Phase 4 | 1,600 participants (Anticipated) | Interventional | 2014-09-30 | Active, not recruiting | ||
| Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis-a Multicentre, Prospective, Double-blind, Double-dummy, Randomized Controlled Clinical Trial[NCT02063100] | Phase 4 | 720 participants (Anticipated) | Interventional | 2014-02-28 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for losartan and Bright Disease
| Article | Year |
|---|---|
Meta-analysis of the effectiveness and safety of Shenyankangfu tablets combined with losartan potassium in the treatment of chronic glomerulonephritis.
Topics: Cytokines; Drug Combinations; Drugs, Chinese Herbal; Glomerulonephritis; Humans; Losartan; Randomize | 2022 |
11 trials available for losartan and Bright Disease
| Article | Year |
|---|---|
Efficacy and safety of Abelmoschus manihot for primary glomerular disease: a prospective, multicenter randomized controlled clinical trial.
Topics: Abelmoschus; Adult; Biopsy; China; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Glomeru | 2014 |
Efficacy and safety of Abelmoschus manihot for primary glomerular disease: a prospective, multicenter randomized controlled clinical trial.
Topics: Abelmoschus; Adult; Biopsy; China; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Glomeru | 2014 |
Efficacy and safety of Abelmoschus manihot for primary glomerular disease: a prospective, multicenter randomized controlled clinical trial.
Topics: Abelmoschus; Adult; Biopsy; China; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Glomeru | 2014 |
Efficacy and safety of Abelmoschus manihot for primary glomerular disease: a prospective, multicenter randomized controlled clinical trial.
Topics: Abelmoschus; Adult; Biopsy; China; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Glomeru | 2014 |
Efficacy and safety of Shenyankangfu tablets for primary glomerulonephritis: study protocol for a randomized controlled trial.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Biomarkers; China; Clinical Protocols | 2014 |
[Multi-center randomized control study on the effects of syndrome differentiated traditional Chinese medicine therapy on CKD 1-2 with chronic nephritis proteinuria].
Topics: Cell Differentiation; Drugs, Chinese Herbal; Glomerular Filtration Rate; Glomerulonephritis; Humans; | 2015 |
Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2003 |
[Serum TIMP-1 concentration in patients with chronic glomerulonephritis and the effect of losartan].
Topics: Adolescent; Adult; Chronic Disease; Female; Fibrosis; Glomerulonephritis; Humans; Kidney; Losartan; | 2003 |
Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis.
Topics: Adult; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypert | 2004 |
Low-dose angiotensin II receptor antagonists and angiotensin II-converting enzyme inhibitors alone or in combination for treatment of primary glomerulonephritis.
Topics: Adult; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2004 |
Randomized, controlled study of the effects of losartan versus enalapril in small doses on proteinuria and tubular injury in primary glomerulonephritis.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhy | 2005 |
A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Ben | 2006 |
Comparison of higher dose of losartan treatment with losartan plus carvedilol and losartan plus ramipril in patients with glomerulonephritis and proteinuria.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; C | 2007 |
Short-term effects of angiotensin II receptor blockade in patients with primary glomerulonephritis: pilot study.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Female; Glomerulon | 2002 |
20 other studies available for losartan and Bright Disease
| Article | Year |
|---|---|
Injured Podocytes Are Sensitized to Angiotensin II-Induced Calcium Signaling.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium Signaling; Cells, Cultured; Disease Model | 2020 |
Regression of albuminuria and hypertension and arrest of severe renal injury by a losartan-hydrochlorothiazide association in a model of very advanced nephropathy.
Topics: Acute Kidney Injury; Albuminuria; Aldosterone; Animals; Antihypertensive Agents; Drug Therapy, Combi | 2013 |
Heme oxygenase-1 inducer hemin attenuates the progression of remnant kidney model.
Topics: Animals; Bone Morphogenetic Protein 7; Caspase 3; Disease Progression; Enzyme Induction; Fibrosis; G | 2009 |
[Fibrillary nonamyloid glomerulonephritis: a rare etiology of nephrotic syndrome].
Topics: Coloring Agents; Complement C3; Congo Red; Diagnosis, Differential; Edema; Female; Fluorobenzenes; G | 2011 |
[Effects of angiotension II receptor antagonist on the level ET and NO in the patients with renal hypertension and protection of renal function].
Topics: Adult; Angiotensin Receptor Antagonists; Endothelin-1; Female; Glomerulonephritis; Humans; Hypertens | 2001 |
Local actions of endogenous angiotensin II in injured glomeruli.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Cell Divi | 2004 |
Intrarenal Renin-Angiotensin system is upregulated in experimental model of progressive renal disease induced by chronic inhibition of nitric oxide synthesis.
Topics: Albumins; Angiotensin-Converting Enzyme Inhibitors; Angiotensinogen; Angiotensins; Animals; Antihype | 2004 |
Regression of existing glomerulosclerosis by inhibition of aldosterone.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Animal; Diuretics; Glomerulonephri | 2005 |
[Pharmacogenetics of angiotensin system in non diabetic nephropathy].
Topics: Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel | 2005 |
Renin-angiotensin system blockade is renoprotective in immune complex-mediated glomerulonephritis.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Enalapri | 2008 |
Regression of glomerulosclerosis in subtotally nephrectomized rats: effects of monotherapy with losartan, spironolactone, and their combination.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Collagen Type IV; Desmin; Dihydralazi | 2008 |
Effects of an angiotensin II receptor antagonist on the progression of renal failure in hyperlipidemic Imai rats.
Topics: Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Blood Urea Nitrogen; | 1993 |
Angiotensin II requires PDGF-BB to induce DNA synthesis in rat mesangial cells cultured in an exogenous insulin-free medium.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Becaplermin; Biphenyl Compounds; Cell Div | 1997 |
Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation.
Topics: Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Bl | 1998 |
High-protein diets augment albuminuria in rats with Heymann nephritis by angiotensin II-dependent and -independent mechanisms.
Topics: Albuminuria; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 1998 |
[Polymorphism studies of angiotensin converting enzyme gene in chronic glomerulonephritis].
Topics: Adolescent; Adult; Alleles; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito | 1999 |
Targeting TGF-beta overexpression: maximizing the antifibrotic actions of angiotensin II blockade in anti-Thy1 glomerulonephritis.
Topics: Angiotensin II; Animals; Enalapril; Glomerulonephritis; Losartan; Male; Rats; Rats, Sprague-Dawley; | 1999 |
Angiotensin II blockade and low-protein diet produce additive therapeutic effects in experimental glomerulonephritis.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 2000 |
Anti-proteinuric effect of angiotension II receptor antagonist losartan in cases with glomerular lesions.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Female; Glomerulonephritis; Humans; Kidne | 2001 |
Effect of ANG II receptor antagonist on albuminuria and renal function in passive Heymann nephritis.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Enalapri | 1992 |